Company intelligence / Profile preview

TheWell Bioscience

Monmouth Junction, New Jersey, United Statesthewellbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

TheWell Bioscience develops xeno-free 3D cell culture hydrogels and bioinks that enable advanced tissue engineering, organoid culture, drug screening, and disease modeling. Their flagship VitroGel® platform is widely used by academic labs and pharmaceutical companies to create more physiologically relevant models for preclinical studies. No clinical trial results as the company is a tools/platform provider.

Therapeutic areas: Oncology
Modalities: Hydrogel-based drug delivery therapyInjectable hydrogel systemBioink for 3D bioprinting
Industry: Non-Drug Biotech

Partnerships

Collaborates with over 250 universities/research institutes worldwide and services major pharmaceutical companies

Beyond the preview

Go deeper on TheWell Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TheWell Bioscience.

Explore the full profile